Improving regenerating potential of the heart after myocardial infarction: Factor-based approach

Hwang, Hyeon-Shik; Kloner, Robert A.

doi:10.1016/j.lfs.2010.01.004

Cited by 30 publications

(15 citation statements)

References 128 publications

(145 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As well discussed by Vandervelde and co-workers, there are many signaling factors released by myocardium after injury that induce mobilization and homing of bone marrow-derived stem cells from peripheral blood to the site of cardiac damage [12]. Among these factors, hematopoietic factors (granulocyte-colony stimulating factor, G-CSF and stem cell factor, SCF), Interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-), vascular endothelial growth factor (VEGF), SDF-1 (together with its receptor CXCR4), fibroblast growth factor (FGF), IGF, HGF, platelet-derived growth factor (PDGF), and others, seem to play pivotal roles in mobilization, homing, proliferation, differentiation, and cardiac protection [12][13][14]. Pathological conditions of cardiac tissue are also related to the onset of oxidative stress cascade, leading to the activation of prosurvival responses such as the expression of erythropoietin (EPO) [12], cyclooxygenase-2 and heme oxygenase-1 [15], myeloperoxidase (MPO) [16][17][18] and heat shock proteins (HSPs) [19][20][21][22][23][24][25][26][27], as well as biomarkers of nitrosative stress [18,28].…”

Section: Heart Resident Stem Cells and Their Limitation In Cardiac Rementioning

confidence: 99%

New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells

Corrao¹,

Rocca²,

Iacono³

et al. 2013

CSCR

View full text Add to dashboard Cite

Cardiomyopathies are still the first cause of death in the world. The identification of resident stem cells, comprising those derived from sub-endocardial stroma, suggests the possible self regeneration of the heart under autocrine/paracrine modulation in the cardiac microenvironment. Nevertheless, because of the limited in vivo regeneration potential of damaged cardiac tissue, the use of drugs and ultimately cardiac transplantation remain the common treatments of heart diseases and defects. The differentiative potential of embryonic and mesenchymal stem cells (MSCs) derived from different tissues (such as bone marrow and adipose tissue) was extensively explored in cell therapy for regenerative medicine. Many groups have been focused, in recent years, on isolation, characterization, and differentiation potential of MSCs derived from perinatal (or extraembryonic) tissues, mainly the placenta and the human umbilical cord. In this review, we summarized recent works about the stemness of Wharton's jelly stromal cells and their potential in cardiac regeneration with favourable use in cell therapy and regenerative medicine. The peculiar features of these cells, as the expression of cardiac-specific transcription factors and immunomodulatory molecules suggest that human umbilical cord may be considered as a reliable alternative source of MSC useful for advanced therapy in cardiac regenerative medicine.

show abstract

Section: Heart Resident Stem Cells and Their Limitation In Cardiac Rementioning

confidence: 99%

New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells

Corrao¹,

Rocca²,

Iacono³

et al. 2013

CSCR

View full text Add to dashboard Cite

show abstract

“…An effective angiogenesis-based therapy can be developed when a comprehensive understanding of angiogenic mechanisms becomes available [8, 9]. Repair and regeneration strategies should focus on utilizing the growth factors (GFs) that play vital roles in the process of angiogenesis, as well as the need to administer them spatiotemporally and in bioactive conformations [6, 7, 10–12]. …”

Section: Introductionmentioning

confidence: 99%

Sequential delivery of angiogenic growth factors improves revascularization and heart function after myocardial infarction

Awada

Johnson

Wang

2015

Journal of Controlled Release

110

View full text Add to dashboard Cite

Treatment of ischemia through therapeutic angiogenesis faces significant challenges. Growth factor (GF)-based therapies can be more effective when concerns such as GF spatiotemporal presentation, bioactivity, bioavailability, and localization are addressed. During angiogenesis, vascular endothelial GF (VEGF) is required early to initiate neovessel formation while platelet-derived GF (PDGF-BB) is needed later to stabilize the neovessels. The spatiotemporal delivery of multiple bioactive GFs involved in angiogenesis, in a close mimic to physiological cues, holds great potential to treat ischemic diseases. To achieve sequential release of VEGF and PDGF, we embed VEGF in fibrin gel and PDGF in a heparin-based coacervate that is distributed in the same fibrin gel. In vitro, we show the benefits of this controlled delivery approach on cell proliferation, chemotaxis, and capillary formation. A rat myocardial infarction (MI) model demonstrated the effectiveness of this delivery system in improving cardiac function, ventricular wall thickness, angiogenesis, cardiac muscle survival, and reducing fibrosis and inflammation in the infarct zone compared to saline, empty vehicle, and free GFs. Collectively, our results show that this delivery approach mitigated the injury caused by MI and may serve as a new therapy to treat ischemic hearts pending further examination.

show abstract

“…In addition, since cardiomyocytes are differentiated cells and primary myocardial tumors are exceedingly rare, malignant transformation would be unlikely. Thus, if it can be translated to the clinic, administration of recombinant proteins for the stimulation of cardiac repair has several promising features (36,47).…”

Section: Introductionmentioning

confidence: 99%

The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation

Wadugu

Kühn

2012

American Journal of Physiology-Heart and Circulatory Physiology

115

View full text Add to dashboard Cite

Wadugu B, Kühn B. The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. Am J Physiol Heart Circ Physiol 302: H2139 -H2147, 2012. First published March 16, 2012 doi:10.1152/ajpheart.00063.2012.-The signaling complex consisting of the growth factor neuregulin-1 (NRG1) and its tyrosine kinase receptors ErbB2 and ErbB4 has a critical role in cardiac development and homeostasis of the structure and function of the adult heart. Recent research results suggest that targeting this signaling complex may provide a viable strategy for treating heart failure. Clinical trials are currently evaluating the effectiveness and safety of intravenous administration of recombinant NRG1 formulations in heart failure patients. Endogenous as well as administered NRG1 has multiple possible activities in the adult heart, but how these are related is unknown. It has recently been demonstrated that NRG1 administration can stimulate proliferation of cardiomyocytes, which may contribute to repair failing hearts. This review summarizes the current knowledge of how NRG1 and its receptors control cardiac physiology and biology, with special emphasis on its role in cardiomyocyte proliferation during myocardial growth and regeneration. cardiac repair; cardiac regeneration; cardiomyocyte differentiation THIS ARTICLE is part of a collection on Physiological Basis of Cardiovascular Cell and Gene Therapies. Other articles appearing in this collection, as well as a full archive of all collections, can be found online at http://ajpheart.physiology. org/.

show abstract

Improving regenerating potential of the heart after myocardial infarction: Factor-based approach

Cited by 30 publications

References 128 publications

New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells

New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells

Sequential delivery of angiogenic growth factors improves revascularization and heart function after myocardial infarction

The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation

Contact Info

Product

Resources

About